2,6,7,8 substituted purines as HDM2 inhibitors

US9540377B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Carolyn Michele Cammarano · Newton, US
• Matthew Christopher · Brookline, US
• Christopher J. Dinsmore · Schwenksville, US
• Ronald J. Doll · Maplewood, US
• Francesc Xavier Fradera Llinas · Brookline, US
• Chaomin Li · Boston, US
• Michelle R. Machacek · Brookline, US
• Michelle Martinez · Salem, US
• Latha G. Nair · Edison, US
• Weidong Pan · Somerville, US
• Michael H. Reutershan · Watertown, US
• Manami Shizuka · Lexington, US
• Dietrich P. Steinhuebel · Boston, US
• Binyuan Sun · Sharon, US
• Christopher F. Thompson · Arlington, US
• B. Wesley Trotter · Medfield, US
• Yaolin Wang · Short Hills, US
• Liping Yang · Arlington, US
• Stephane L. Bogen · Somerville, US
• Matthew E. Voss · Singapore, SG
• Jagannath Panda · Singapore, SG
• Anthappan Tony Kurissery · Singapore, SG

Key dates

• Filing date: Jan 29, 2014
• Grant date: Jan 10, 2017
• Expiry date: Jan 29, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D473/34
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.